Cox models adjusted for IPI factors for EFS and OS for patients treated with rituximab
| . | n* . | EFS . | OS . | |||||
|---|---|---|---|---|---|---|---|---|
| . | Positive . | Negative . | RR . | 95% CI . | P value . | RR . | 95% CI . | P value . |
| FISH | ||||||||
| MYC break + | 19 | 185 | 1.6 | 0.8-3.2 | 0.162 | 1.8 | .8-3.9 | 0.132 |
| BCL2 break + | 28 | 166 | 0.9 | 0.5-1.8 | 0.800 | 1.5 | 0.7-3.0 | 0.302 |
| BCL6 break + | 55 | 144 | 0.8 | 0.4-1.3 | 0.364 | 0.5 | 0.3-1.1 | 0.078 |
| IHC | ||||||||
| MYC IHC (41%-100%) | 43 | 98 | 2.2 | 1.3-3.9 | 0.005 | 2.5 | 1.3-4.8 | 0.005 |
| BCL2 IHC (1%-100%) | 158 | 43 | 1.9 | 1.0-3.8 | 0.064 | 2.4 | 1.0-5.5 | 0.039 |
| BCL6 IHC (0%-25%) | 142 | 34 | 2.2 | 1.3-3.8 | 0.003 | 2.1 | 1.1-3.8 | 0.020 |
| IHC, model 1, n = 137 | ||||||||
| MYC IHC (41%-100%) | 43 | 94 | 2.2 | 1.2-3.8 | 0.007 | 2.4 | 1.2-4.6 | 0.013 |
| BCL2 IHC (1%-100%) | 110 | 27 | 3.4 | 1.3-9.0 | 0.013 | 5.1 | 1.4-18.0 | 0.012 |
| IHC, model 2, n= 138 | ||||||||
| MYC IHC (41%-100%) | 43 | 95 | 2.2 | 1.3-3.9 | 0.006 | 2.4 | 1.2-4.8 | 0.010 |
| BCL6 IHC (0%-25%) | 113 | 25 | 2.3 | 1.2-4.4 | 0.009 | 1.8 | 0.9-3.9 | 0.115 |
| IHC, model 3, n= 170 | ||||||||
| BCL2 IHC (1%-100%) | 132 | 38 | 1.5 | 0.8-3.1 | 0.228 | 1.9 | 0.8-4.5 | 0.144 |
| BCL6 IHC (0%-25%) | 136 | 34 | 2.2 | 1.3-3.8 | 0.004 | 2.0 | 1.1-3.7 | 0.035 |
| IHC, model 4, n = 135 | ||||||||
| MYC IHC (41%-100%) | 43 | 92 | 2.2 | 1.2-3.9 | 0.009 | 2.3 | 1.2-4.7 | 0.019 |
| BCL2 IHC (1%-100%) | 108 | 27 | 3.0 | 1.1-7.8 | 0.029 | 4.5 | 1.3-16.2 | 0.020 |
| BCL6 IHC (0%-25%) | 110 | 25 | 2.1 | 1.1-3.9 | 0.025 | 1.5 | 0.7-3.2 | 0.338 |
| FISH/IHC, model 1, n = 133 | ||||||||
| MYC break + | 14 | 119 | 1.5 | 0.6-3.4 | 0.361 | 2.1 | 0.8-5.5 | 0.151 |
| MYC IHC (41%-100%) | 41 | 92 | 2.0 | 1.1-3.7 | 0.030 | 2.1 | 1.0-4.4 | 0.063 |
| FISH/IHC, model 2, n = 186 | ||||||||
| MYC break + | 18 | 168 | 1.5 | 0.7-3.1 | 0.272 | 1.8 | 0.8-4.0 | 0.142 |
| BCL2 IHC (1%-100%) | 144 | 42 | 2.1 | 1.0-4.4 | 0.040 | 2.7 | 1.1-6.7 | 0.029 |
| FISH/IHC, model 3, n = 164 | ||||||||
| MYC break + | 19 | 145 | 1.9 | 0.9-3.8 | 0.074 | 2.1 | 1.0-4.7 | 0.062 |
| BCL6 IHC (0%-25%) | 131 | 33 | 2.4 | 1.4-4.1 | 0.003 | 2.4 | 1.2-4.5 | 0.009 |
| FISH/IHC, model 4, n = 158 | ||||||||
| MYC break + | 18 | 140 | 1.7 | 0.8-3.7 | 0.141 | 2.2 | 1.0-5.0 | 0.057 |
| BCL2 IHC (1%-100%) | 121 | 37 | 1.7 | 0.8-3.5 | 0.186 | 2.0 | 0.8-5.1 | 0.144 |
| BCL6 IHC (0%-25%) | 125 | 33 | 2.3 | 1.3–4.1 | 0.005 | 2.2 | 1.1–4.3 | 0.020 |
| FISH/IHC, model 5, n = 127 | ||||||||
| MYC break + | 14 | 113 | 1.5 | 0.6-3.5 | 0.402 | 1.8 | 0.6-5.3 | 0.259 |
| MYC IHC (41%-100%) | 41 | 86 | 1.9 | 1.0–3.7 | 0.052 | 1.8 | 0.8–4.2 | 0.159 |
| BCL2 IHC (1%-100%) | 100 | 27 | 2.7 | 1.0-7.2 | 0.049 | 3.8 | 1.0-14.1 | 0.045 |
| BCL6 IHC (0%-25%) | 102 | 25 | 2.2 | 1.2–4.3 | 0.016 | 1.8 | 0.8–4.0 | 0.156 |
| . | n* . | EFS . | OS . | |||||
|---|---|---|---|---|---|---|---|---|
| . | Positive . | Negative . | RR . | 95% CI . | P value . | RR . | 95% CI . | P value . |
| FISH | ||||||||
| MYC break + | 19 | 185 | 1.6 | 0.8-3.2 | 0.162 | 1.8 | .8-3.9 | 0.132 |
| BCL2 break + | 28 | 166 | 0.9 | 0.5-1.8 | 0.800 | 1.5 | 0.7-3.0 | 0.302 |
| BCL6 break + | 55 | 144 | 0.8 | 0.4-1.3 | 0.364 | 0.5 | 0.3-1.1 | 0.078 |
| IHC | ||||||||
| MYC IHC (41%-100%) | 43 | 98 | 2.2 | 1.3-3.9 | 0.005 | 2.5 | 1.3-4.8 | 0.005 |
| BCL2 IHC (1%-100%) | 158 | 43 | 1.9 | 1.0-3.8 | 0.064 | 2.4 | 1.0-5.5 | 0.039 |
| BCL6 IHC (0%-25%) | 142 | 34 | 2.2 | 1.3-3.8 | 0.003 | 2.1 | 1.1-3.8 | 0.020 |
| IHC, model 1, n = 137 | ||||||||
| MYC IHC (41%-100%) | 43 | 94 | 2.2 | 1.2-3.8 | 0.007 | 2.4 | 1.2-4.6 | 0.013 |
| BCL2 IHC (1%-100%) | 110 | 27 | 3.4 | 1.3-9.0 | 0.013 | 5.1 | 1.4-18.0 | 0.012 |
| IHC, model 2, n= 138 | ||||||||
| MYC IHC (41%-100%) | 43 | 95 | 2.2 | 1.3-3.9 | 0.006 | 2.4 | 1.2-4.8 | 0.010 |
| BCL6 IHC (0%-25%) | 113 | 25 | 2.3 | 1.2-4.4 | 0.009 | 1.8 | 0.9-3.9 | 0.115 |
| IHC, model 3, n= 170 | ||||||||
| BCL2 IHC (1%-100%) | 132 | 38 | 1.5 | 0.8-3.1 | 0.228 | 1.9 | 0.8-4.5 | 0.144 |
| BCL6 IHC (0%-25%) | 136 | 34 | 2.2 | 1.3-3.8 | 0.004 | 2.0 | 1.1-3.7 | 0.035 |
| IHC, model 4, n = 135 | ||||||||
| MYC IHC (41%-100%) | 43 | 92 | 2.2 | 1.2-3.9 | 0.009 | 2.3 | 1.2-4.7 | 0.019 |
| BCL2 IHC (1%-100%) | 108 | 27 | 3.0 | 1.1-7.8 | 0.029 | 4.5 | 1.3-16.2 | 0.020 |
| BCL6 IHC (0%-25%) | 110 | 25 | 2.1 | 1.1-3.9 | 0.025 | 1.5 | 0.7-3.2 | 0.338 |
| FISH/IHC, model 1, n = 133 | ||||||||
| MYC break + | 14 | 119 | 1.5 | 0.6-3.4 | 0.361 | 2.1 | 0.8-5.5 | 0.151 |
| MYC IHC (41%-100%) | 41 | 92 | 2.0 | 1.1-3.7 | 0.030 | 2.1 | 1.0-4.4 | 0.063 |
| FISH/IHC, model 2, n = 186 | ||||||||
| MYC break + | 18 | 168 | 1.5 | 0.7-3.1 | 0.272 | 1.8 | 0.8-4.0 | 0.142 |
| BCL2 IHC (1%-100%) | 144 | 42 | 2.1 | 1.0-4.4 | 0.040 | 2.7 | 1.1-6.7 | 0.029 |
| FISH/IHC, model 3, n = 164 | ||||||||
| MYC break + | 19 | 145 | 1.9 | 0.9-3.8 | 0.074 | 2.1 | 1.0-4.7 | 0.062 |
| BCL6 IHC (0%-25%) | 131 | 33 | 2.4 | 1.4-4.1 | 0.003 | 2.4 | 1.2-4.5 | 0.009 |
| FISH/IHC, model 4, n = 158 | ||||||||
| MYC break + | 18 | 140 | 1.7 | 0.8-3.7 | 0.141 | 2.2 | 1.0-5.0 | 0.057 |
| BCL2 IHC (1%-100%) | 121 | 37 | 1.7 | 0.8-3.5 | 0.186 | 2.0 | 0.8-5.1 | 0.144 |
| BCL6 IHC (0%-25%) | 125 | 33 | 2.3 | 1.3–4.1 | 0.005 | 2.2 | 1.1–4.3 | 0.020 |
| FISH/IHC, model 5, n = 127 | ||||||||
| MYC break + | 14 | 113 | 1.5 | 0.6-3.5 | 0.402 | 1.8 | 0.6-5.3 | 0.259 |
| MYC IHC (41%-100%) | 41 | 86 | 1.9 | 1.0–3.7 | 0.052 | 1.8 | 0.8–4.2 | 0.159 |
| BCL2 IHC (1%-100%) | 100 | 27 | 2.7 | 1.0-7.2 | 0.049 | 3.8 | 1.0-14.1 | 0.045 |
| BCL6 IHC (0%-25%) | 102 | 25 | 2.2 | 1.2–4.3 | 0.016 | 1.8 | 0.8–4.0 | 0.156 |
Sample sizes differ because of complete data set per Cox model.